Cancer often develops through the disruption of proper responses to extracellular signals. Thus, understanding how normal cells sense and generate proper responses to changes in environment is important. Normally, transduction of extracellular signals into cellular responses involves a cascade of biochemical events that eventually induce gene expression. These events are mediated by transcription factors (TF), a class of DNA-binding proteins which dictate the nature of genes expressed. Deregulation of TF activities can lead to amplification of anomalies via uncontrolled gene expression. Activation of a critical TF, NF-kappaB, by extracellular signals normally occurs only transiently since NF-kappaB activates synthesis of its own inhibitor, IkappaBalpha. By contrast, deregulation of NF-kappaB activity, frequently seen in human cancers, must counteract this feedback mechanism to maintain constitutive (constant) NF-kappaB activation. How and why is NF-kappaB anomalously activated? Research in this laboratory has demonstrated that murine B cells, a rare example with non-pathological constitutive NF- kappaB activation, maintain such activity by degrading newly synthesized IkappaBalpha via a previously uncharacterized mechanism. Our preliminary data also suggest that certain human breast cancer cells aberrantly activate NF-kappaB by utilizing this alternative mechanism. Thus, the proposed research will test the hypothesis that a novel IkappaBalpha degradation mechanism is required for constitutive NF- kappaB activation in B cells and certain human breast cancer cells.
In aim 1, mutational analysis will be employed to identify IkappaBalpha sequences that specify degradation by this novel pathway.
Under Aim 2, the functional role of this alternative pathway will be determined in both induction and maintenance phases of constitutive NF-kappaB activation in B cells, by further specifying how proteasome-dependent NF-kappaB activation becomes proteasome-independent via a switch in IkappaBalpha degradation mechanisms.
Aim 3 will test the mechanism and role of constitutive NF-kappaB activation in breast cancer cells by focusing on the alternative IkappaBalpha degradation in relation to cell survival function. This research program will provide not only a mechanistic insight into how an alternative pathway restricted to normal B cell function may be abnormally employed by cancer cells by also molecular reagent tools to probe other constitutive NF-kappaB activation systems.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA081065-02
Application #
6150380
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Gallahan, Daniel L
Project Start
1999-04-01
Project End
2003-01-31
Budget Start
2000-06-01
Budget End
2001-01-31
Support Year
2
Fiscal Year
2000
Total Cost
$188,531
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Stallcop, Loren E; Álvarez-García, Yasmín R; Reyes-Ramos, Ana M et al. (2018) Razor-printed sticker microdevices for cell-based applications. Lab Chip 18:451-462
Young, Edmond W K; Pak, Chorom; Kahl, Brad S et al. (2012) Microscale functional cytomics for studying hematologic cancers. Blood 119:e76-85
Lee, Moon Hee; Mabb, Angela M; Gill, Grace B et al. (2011) NF-?B induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell 43:180-91
Wuerzberger-Davis, Shelly M; Chen, Yuhong; Yang, David T et al. (2011) Nuclear export of the NF-?B inhibitor I?B? is required for proper B cell and secondary lymphoid tissue formation. Immunity 34:188-200
Markovina, Stephanie; Callander, Natalie S; O'Connor, Shelby L et al. (2008) Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6:1356-64
Ni, Chang-Yuan; Wu, Zhao-Hui; Florence, William C et al. (2008) Cutting edge: K63-linked polyubiquitination of NEMO modulates TLR signaling and inflammation in vivo. J Immunol 180:7107-11
Wuerzberger-Davis, S M; Nakamura, Y; Seufzer, B J et al. (2007) NF-kappaB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. Oncogene 26:641-51
Berchtold, Craig M; Wu, Zhao-Hui; Huang, Tony T et al. (2007) Calcium-dependent regulation of NEMO nuclear export in response to genotoxic stimuli. Mol Cell Biol 27:497-509
Chang, Pei-Yun; Draheim, Kyle; Kelliher, Michelle A et al. (2006) NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res 66:6008-13
Chang, Pei-Yun; Miyamoto, Shigeki (2006) Nuclear factor-kappaB dimer exchange promotes a p21(waf1/cip1) superinduction response in human T leukemic cells. Mol Cancer Res 4:101-12

Showing the most recent 10 out of 22 publications